Published March 22, 2023 | Version 1

4-year survival and biomarkers evaluation from a phase II study of sequential immunotherapy and targeted therapy for metastatic BRAF V600-mutated melanoma (SECOMBIT)

Description

4-year survival data of clinical trial SECOMBIT

Files

protocol_21.02961_cover-page.pdf

Files (178.5 MB)

Name Size Download all
md5:7dc671f331b1e563317f35f42b64db85
90.1 kB Preview Download
md5:325a028b37ef9b5436850b443c311c37
2.7 MB Preview Download
md5:1c3935002f0a900f5ba6b34fbdd8d385
417.9 kB Preview Download
md5:9600d0d712cde66aa7b3868e79b5c028
1.6 MB Preview Download
md5:cc4e6618d8bb362aa46da025a08e0d47
1.9 MB Preview Download
md5:582cde8c0c1708fc396f7c791a47a183
18.2 kB Download
md5:2bab7c0e49fe6e402a1f16fd2cf46144
26.0 kB Download
md5:10c28a823543e0a2571f022a8dba155b
171.8 MB Preview Download